A cyclic peptide compound having binding affinity to il-4ra and applications thereof

Cyclic peptide compounds obtained through phage display technology overcome the shortcomings of existing IL-4Rα monoclonal antibody drugs, achieving high affinity and stability, and effectively blocking IL-4 and IL-13 signaling, making them suitable for the treatment of Th2 inflammatory diseases.

CN122127407APending Publication Date: 2026-06-02SHANGHAI MERNA THERAPEUTICS CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
SHANGHAI MERNA THERAPEUTICS CO LTD
Filing Date
2026-05-06
Publication Date
2026-06-02

AI Technical Summary

Technical Problem

Existing monoclonal antibody drugs targeting IL-4Rα have high production costs, require low-temperature storage, are inconvenient to administer, and pose potential immunogenic risks. Furthermore, they may not provide adequate response or adequate symptom control and cannot effectively block IL-4 and IL-13 signaling.

Method used

Cyclic peptide compounds with high affinity and selectivity for IL-4Rα were obtained by screening using phage display technology. The amino acid sequence is Cys-Aaa2-Aaa3-Aaa4-Aaa5-Aaa6-Aaa7-Aaa8-Cys, which form disulfide bonds to constitute a cyclic peptide for blocking IL-4 and IL-13 signal transduction.

Benefits of technology

It provides cyclic peptide compounds with excellent binding affinity and stability, which can effectively block the binding of IL-4Rα to IL-4 or IL-13, for the treatment of Th2 inflammatory diseases such as atopic dermatitis, asthma and fibrotic diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The present application relates to a kind of cyclic peptide compounds with binding affinity to IL-4R alpha and its application.The amino acid sequence of the cyclic peptide compound includes the sequence shown in SEQ ID NO.2 or SEQ ID NO.6.The cyclic peptide compound provided by the present application can specifically bind to cytokine IL-4 receptor alpha, so that IL-4R alpha is enriched, has good inhibitory effect on IL-4 and IL-13 signal pathway, and can be applied to treat IL-4R alpha related diseases.
Need to check novelty before this filing date? Find Prior Art